Latest Schedule 13G passive stakes

American Century Capital Portfolios, Inc., American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have jointly filed a Schedule 13G, reporting a combined beneficial ownership of 11.8% of Entravision Communications Corporation's Class A Common Stock.

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 5.0% of AnaptysBio, Inc. common stock as of June 30, 2026.

Oasis Management Company Ltd. and Seth Fischer have reported beneficial ownership of 2,329,018 shares, representing 6.5% of Vail Resorts Inc.'s common stock.

Fidelity National Financial, Inc. has disclosed beneficial ownership of 5,937,500 shares, representing 5.2% of the total voting power of Aevex Corp.'s Class A Common Stock.

Fidelity National Financial, Inc. has disclosed beneficial ownership of 5,937,500 shares, representing 5.2% of the total voting power of Aevex Corp.'s Class A Common Stock.

American Century ETF Trust, American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have collectively increased their beneficial ownership of DXC Technology Company's common stock to 6.4%.

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 6.2% of Alto Neuroscience, Inc. common stock, including shares issuable upon warrant exercise.

American Century Investment Management, Inc., along with its affiliates, has updated its beneficial ownership of Compass Diversified Holdings, now holding 5.4% of the common stock.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 9.74% of MoonLake Immunotherapeutics' Class A ordinary shares.

American Century ETF Trust, American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have collectively disclosed beneficial ownership of over 5% of Civeo Corporation's common stock.

Deep Track Capital, LP, along with affiliated entities, has reported beneficial ownership of 3.64% of MBX Biosciences, Inc. common stock as of June 30, 2026.

Arcbest Corporation's Schedule 13G filing reveals substantial beneficial ownership by American Century entities and Stowers Institute, totaling over 12% of common stock.

Investment firm Deep Track Capital, along with its affiliates, has reported beneficial ownership of 9,341,151 shares, representing 4.55% of Immunovant, Inc.'s common stock.

American Century Investment Management, Inc. and its affiliates have reported a 6.6% beneficial ownership of Albany International Corp.'s Class A Common Stock as of June 30, 2026.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have collectively acquired a 4.97% stake in Enanta Pharmaceuticals, Inc., as disclosed in a Schedule 13G filing.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have reported a 0.0% beneficial ownership of enGene Therapeutics Inc. common shares as of June 30, 2026, indicating a complete divestment.

Farallon Capital Management and affiliated entities have filed a Schedule 13G, reporting a passive ownership stake in Tyra Biosciences, Inc.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 3,610,000 shares, representing 6.87% of Avalo Therapeutics, Inc. common stock.

Farallon Capital Management and affiliated entities have reported beneficial ownership of 9.8% of Tango Therapeutics' common stock, primarily through warrants and shares.

Farallon Capital Management, L.L.C. and associated entities have reported beneficial ownership of 3,325,000 ordinary shares, representing 2.3% of the class, in InflaRx N.V.

Several PEAK6 affiliated entities and individuals have filed a Schedule 13G, reporting a collective beneficial ownership of 2.5% in eToro Group Ltd. Class A common shares.

Farallon Capital Management, L.L.C. has filed a Schedule 13G, reporting beneficial ownership of 8.3% of Enanta Pharmaceuticals Inc. common stock as of June 30, 2026.

RTW Investments, LP and Roderick Wong, M.D. have filed a Schedule 13G, disclosing beneficial ownership of 5.7% of uniQure N.V.'s ordinary shares as of June 30, 2026.

RTW Investments, LP and Roderick Wong, M.D. have filed a Schedule 13G, disclosing beneficial ownership of 7,796,895 shares of Ultragenyx Pharmaceutical Inc. common stock, representing 7.9% of the class.

RTW Investments, LP and Roderick Wong report beneficial ownership of 2,866,654 shares, representing 9.9% of Tenax Therapeutics, Inc.'s common stock, as of June 30, 2026.

RTW Investments, LP and Roderick Wong have disclosed a beneficial ownership of 4,251,996 shares, representing 4.8% of Spyre Therapeutics, Inc.'s common stock.

RTW Investments, LP, through its managing partner Roderick Wong, has increased its beneficial ownership of RadNet, Inc. common stock to 6.2%, acquiring 4,846,958 shares.

Hood River Capital Management LLC has disclosed beneficial ownership of 7.16% of Red Cat Holdings, Inc. common stock as of June 30, 2026.

Hood River Capital Management LLC has reported a beneficial ownership of 5.37% in LightPath Technologies Inc. as of June 30, 2026.

Hood River Capital Management LLC has disclosed beneficial ownership of 7.64% of Bandwidth Inc.'s common stock as of June 30, 2026.